Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world settingFlorian Rosar, Fadi Khreish, Caroline Burgard, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|October 7, 2024
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancerCaroline Burgard, Florian Rosar, Elena Larsen, et al.
European Radiology|February 28, 2015
Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancerWolfgang Peter Fendler, Harun Ilhan, Philipp M Paprottka, et al.
Clinical Nuclear Medicine|May 13, 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient CohortMoritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Journal of Cancer Research and Clinical Oncology|March 21, 2017
Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolizationFrederic Carsten Schmeel, Birgit Simon, Julian Alexander Luetkens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2014
Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading systemSamer Ezziddin, Linda Adler, Amir Sabet, et al.
Inorganic Chemistry|October 1, 2024
Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn2+, Cu2+, Zn2+, Ga3+, In3+, Tb3+, and Lu3Ina Hierlmeier, Nadia Marino, Moritz-Valentin Schreck, et al.
Cancers|October 26, 2024
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand TherapyCaroline Burgard, Fadi Khreish, Lukas Dahlmanns, et al.
Clinical Nuclear Medicine|May 4, 2026
Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617Florian Rosar, Caroline Burgard, Sophia Phuong Thao Hoang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007Caroline Burgard, Madita Frei, Arne Blickle, et al.
Pageof 16